) The Cell Analysis Core is designed to provide support to the clinical and basic projects by centralizing common procedures. These include sample acquisition, characterization, distribution and storage, cell sorting, analytical flow cytometry, histology and immunohistochemistry, and fluorescence in situ hybridization (FISH). By centralizing sample acquisition, we will be able to maintain records of expected data for each sample used, thus, increasing the efficiency of data collection. A priority list for sample distribution will be established and updated periodically to accommodate requirements of the different projects in terms of cell numbers, sample type, patient characteristics, and other relevant criteria. This mechanism will greatly enhance the efficiency of sample utilization by the different projects. A centralized histology, immunohistochemistry, and FISH service will avoid the need to establish the procedures in each investigator?s laboratory, providing for uniformity of procedures and efficient use of materials. The flow cytometry and cell sorting service offered will provide state-of-the-art flow cytometry and cell sorting support to the projects in this program application. The different functions of the core will be supervised by able individuals with ample experienced in the various procedures.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA055819-08
Application #
6594587
Study Section
Subcommittee G - Education (NCI)
Project Start
2002-06-01
Project End
2003-05-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
8
Fiscal Year
2002
Total Cost
$279,549
Indirect Cost
Name
University of Arkansas for Medical Sciences
Department
Type
DUNS #
City
Little Rock
State
AR
Country
United States
Zip Code
72205
Rasche, L; Alapat, D; Kumar, M et al. (2018) Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma. Leukemia :
Went, Molly; Sud, Amit; Försti, Asta et al. (2018) Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. Nat Commun 9:3707
Mehdi, Syed J; Johnson, Sarah K; Epstein, Joshua et al. (2018) Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytes. Br J Haematol :
Rasche, Leo; Angtuaco, Edgardo J; Alpe, Terri L et al. (2018) The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma. Blood 132:59-66
Rasche, Leo; Angtuaco, Edgardo; McDonald, James E et al. (2017) Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. Blood 130:30-34
Mikulasova, Aneta; Wardell, Christopher P; Murison, Alexander et al. (2017) The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma. Haematologica 102:1617-1625
Stein, Caleb K; Pawlyn, Charlotte; Chavan, Shweta et al. (2017) The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma. Oncotarget 8:27854-27867
Chavan, S S; He, J; Tytarenko, R et al. (2017) Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker. Blood Cancer J 7:e535
Went, M; Sud, A; Law, P J et al. (2017) Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approach. Blood Cancer J 7:e573
McDonald, James E; Kessler, Marcus M; Gardner, Michael W et al. (2017) Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma. Clin Cancer Res 23:1981-1987

Showing the most recent 10 out of 290 publications